Raloxifene: A selective estrogen-receptor modulator for postmenopausal osteoporosis - A clinical update on efficacy and safety

Women's Health

Volumn 2, Issue 2, 2006, Pages 199-210

  Deal, Chad L ^a   Draper, Michael W ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Clinical trial; Fracture; Osteoporosis; Postmenopausal; Raloxifene; Selective estrogen receptor modulator; Women's health

Indexed keywords

BENZOTHIOPHENE DERIVATIVE; CALCIUM; CENTCHROMAN; CLOMIFENE; COLECALCIFEROL; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN RECEPTOR; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BINDING AFFINITY; BREAST CANCER; CALCIUM METABOLISM; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; COGNITIVE DEFECT; CONFORMATION; DATA ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; HOT FLUSH; HUMAN; INCIDENCE; LEG CRAMP; METABOLIC DISORDER; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK REDUCTION; SKELETON; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; URINE INCONTINENCE; UTERUS BLEEDING; UTERUS PROLAPSE; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

EID: 33646799836     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.2.2.199     Document Type: Review

References (125)

1. Shang Y, Brown M: Molecular determinants for the tissue specificity of SERMs. Science 295(5564), 2465-2468 (2002).
2. Katzenellenbogen BS, Katzenellenbogen JA: Biomedicine. Defining the "S" in SERMs. Science 295(5564), 2380-2381 (2002).
3. Kousteni S, Han L, Chen JR et al.: Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J. Clin. Invest. 111(11), 1651-1664 (2003).
4. Draper MW, Chin WW: Molecular and clinical evidence for the unique nature of individual selective estrogen receptor modulators. Clin. Obstet. Gynecol. 46(2), 265-297 (2003).
5. Sporn MB, Dowsett SA, Mershon J, Bryant HU: Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action. Clin. Ther. 26(6), 830-840 (2004).
6. Jordan VC: Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J. Med. Chem. 46(7), 1081-1111 (2003).
7. Buzdar AU, Marcus C, Holmes F, Hug V. Hortobagyi G: Phase II evaluation of LY156758 in metastatic breast cancer. Oncology 45(5), 344-345 (1988).
8. Bryant HU: Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulation. Rev. Endocr. Metab. Disord. 2(1), 129-138 (2001).
9. Draper MW, Flowers DE, Huster WJ et al.: A controlled trial of raloxifene (LY139481) HC1: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J. Bone Miner. Res. 11(6), 835-842 (1996).
10. Delmas PD, Bjarnason NH, Mitlak BH et al.: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337(23), 1641-1647 (1997).
11. Johnston CC Jr, Bjarnason NH, Cohen FJ et al.: Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipids in early postmenopausal women. 3-year data from two double-blind, randomized, placebo-controlled trials. Arch. Intern. Med. 160(22), 3444-3450 (2000).
12. Jolly EE, Bjarnason NH, Neven P et al.: Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 10(4), 337-344 (2003).
13. Reid IR, Eastell R, Fogelman I et al.: A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch. Intern. Med. 164(8), 871-879 (2004).
14. Ettinger B, Black DM, Mitlak BH et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282(7), 637-645 (1999).
15. Cummings S, Eckert S, Krueger K et al.: The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 281, 2189-2197 (1999).
16. Martino S, Cauley JA, Barrett-Connor E et al.: Continuing Outcomes Relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl Cancer Inst. 96(23), 1751-1761 (2004).
17. Kanis JA, Johnell O, Black DM et al.: Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 33(3), 293-300 (2003).
18. Prestwood KM, Gunness M, Muchmore DB et al.: A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J. Clin. Endocrinol. Metab. 85(6), 2197-2202 (2000).
19. Weinstein RS, Parfitt AM, Marcus R et al.: Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos. Int. 14(10), 814-822 (2003).
20. Gozansky WS, Van Pelt RE, Jankowski CM, Schwartz RS, Kohrt WM: Protection of bone mass by estrogens and raloxifene during exercise-induced weight loss. J. Clin. Endocrinol. Metab. 90(1), 52-59 (2005).
21. Delmas PD, Ensrud KE, Adachi JD et al.: Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J. Clin. Endocrinol. Metab. 87(8), 3609-3617 (2002).
22. Delmas PD, Genant HK, Crans G et al.: Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33(10), 522-532 (2003).
23. Siris ES, Harris ST, Eastell R et al.: Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J. Bone Miner. Res. 20(9), 1514-1524 (2005).
24. Boivin G, Lips P, Ott SM et al.: Contribution of raloxifene and calcium and vitamin D3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women. J. Clin. Endocrinol. Metab. 88(9), 4199-4205 (2003).
25. Ott SM, Oleksik A, Lu Y, Harper KD, Lips P: Bone histomorphometric and biochemical marker results of a two-year placebo controlled trial of raloxifene in postmenopausal women. J. Bone Miner. Res. 17, 341-348 (2002).
26. Sarkar S, Mitlak BH, Wong M et al.: Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J. Bone Miner. Res. 17(1), 1-10 (2002).
27. Sarkar S, Reginster JY, Crans GG et al.: Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J. Bone Miner. Res. 19(3), 394-401 (2004).
28. Reginster JY, Sarkar S, Zegels B et al.: Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34(2), 344-351 (2004).
29. Johnell O, Kanis JA, Black DM et al.: Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) study. J. Bone Miner. Res. 19(5), 764-772 (2004).
30. Palomba S, Numis FG, Mossetti G et al.: Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes. Hum. Reprod. 18(1), 192-198 (2003).
31. Hansdottir H, Franzson L, Prestwood K, Sigurdsson G: The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities. J. Am. Geriatr Soc. 52(5), 779-783 (2004).
32. Kung AW, Chao HT Huang KE et al.: Efficacy and safety of raloxifene 60 Milligrdms/day in postmenopausal Asian women. J. Clin. Endocrinol. Metab. 88(7), 3130-3136 (2003),
33. Liu J. Zhu H, Huang Q et al.: Effects of raloxifene hydrochloride on bone minderal density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial, Chin. Med. J. (Engl.) 117(7), 1029-1035 (2004).
34. Zheng S, Wu Y, Zhang Z et al.: Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: a randomized clinical trial in Beijing. Chin. Med. J. (Engl.) 116(8), 1127-1133 (2003).
35. Morii H, Ohashi Y, Taketani Y et al.: Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos. Int. 14, 793-800 (2003).
36. Walsh BW, Kuller LH, Wild RA et al.: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279(18), 1445-1451 (1998).
37. Walsh BW, Paul S, Wild RA et al.: The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 85, 214-218 (2000).
38. Walsh BW, Cox DA, Sashegyi A et al.: Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am. J. Cardiol. 88(7), 825-828 (2001).
39. Walsh BW: The effects of estrogen and selective estrogen receptor modulators on cardiovascular risk factors. Ann. NY Acad. Sci. 949, 163-167 (2001).
40. Anderson PW, Cox DA, Sashegyi A et al.: Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women. Maturitas 39, 71-77 (2001).
41. Nickelsen T, Creatsas G, Rechberger T et al.: Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study. Climacteric 4(4), 320-331 (2001).
42. Cox DA, Sarkar S, Harper K, Barrett-Connor E: Effect of raloxifene on the incidence of elevated low density lipoprotein (LDL) and achievement of LDL target goals in postmenopausal women. Curr. Med. Res. Opin. 20(7), 1049-1055 (2004).
43. Duschek EJ, Stehouwer CD, de Valk-de Roo GW et al.: Raloxifene, conjugated oestrogen and endothelial function in postmenopausal women. J. Intern. Med. 254(1), 85-94 (2003).
44. Teerlink T, Neele SJ, de Jong S, Netelenbos JC, Stehouwer CD: Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. Clin. Sci. 105(1), 67-71 (2003).
45. Post MS, van der Mooren MJ, van Baal WM et al.: Raloxifene reduces impedance to flow within the uterine artery in early postmenopausal wornen: a 2-year randomized, placebo-controlled, comparative study. Am. J. Obstet. Gynecol. 185(3), 557-562 (2001).
46. Vogelvang TE, Leurs JR, van der Mooren MJ et al.: Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women. Menopause 11(1). 110-115 (2004).
47. Giltay EJ, Duschek EJ, Katan MB et al.: Raloxifene and hormone replacement therapy increase arachidonic acid and docosahexaenoic acid levels in postmenopausal women. J. Endocrinol. 182(3), 399-408 (2004).
48. Creatsas G, Christodoulakos G. Lambrinoudaki I et al.: Serum lipids and apolipoproteins in Greek postmenopausal women: association with estrogen, estrogen-progestin, tibolone and raloxifene therapy. J. Endocrinol. Invest. 26(6), 545-551 (2003).
49. Christodoulakos GE, Lambrinoudaki IV, Panoulis CP et al.: Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women. Gynecol. Endocrinol. 18(5), 244-257 (2004).
50. Christodoulakos G, Lambrinoudaki I, Panoulis C et al.: Effect of hormone therapy and raloxifene on serum VE-cadherin in postmenopausal women. Fertill. Steril. 82(3), 634-638 (2004).
51. Christodoulakos GE, Panoulis CP, Lambrinoudaki IV et at.: The effect of hormone therapy and raloxifene on serum matrix metalloproteinase-2 and -9 in postmenopausal women. Menopause 11(3), 299-305 (2004).
52. Christodoulakos G, Lambrinoudaki I, Panoulis C et al.: Effect of hormone therapy, tibolone and raloxifene on circulating vascular endothelial growth factor in Greek postmenopausal women. Eur. J. Endocrinol. 151(2), 187-192 (2004).
53. Lam PM, Yim SF, Briton-Jones C, Chung TK, Haines C: Raloxicene therapy in postmenopausal women is associated with a significant reduction in the concentration of serum vascular endothelial growth factor. Fertill. Steril. 81(2), 393-397 (2004).
54. Piperi C, Kalofoutis C, Lagogianni I, Troupis G, Kalofoutis A: Comparison of raloxifene and atorvastatin effects on serum lipids composition of healthy post-menopausal women. Mol. Cell Biochem. 261(1-2), 71-75 (2004).
55. Piperi C, Kalofoutis C, Papapanagiotou A, Skenderi C, Kalofoutis A: Comparative analysis of oestrogen and raloxifene effects on the phospholipid composition of high density lipoproteins in healthy postmenopausal women. J. Obstet. Gynaecol. 24(1), 52-57 (2004).
56. Pipert C, Kaiofoutis C, Skenderi K, Economidou O, Kalofoutis A: Beneficial effects of raloxifene and atorvastatin on serum lipids and HDL phospholipids levels of postmenopausal women. J. Obstet. Gynaecol. 24(4), 414-419 (2004).
57. Sarrel PM, Nawaz H, Chan W, Fuchs M, Katz DL: Raloxifene and endothelial function in healthy postmenopausal women Am. J. Obstet. Gynecol. 188(2), 304-309 (2003).
58. Saitta A, Altavilla D, Cucinotta D et al.: Randomized, double-blind, placebo controlled study on the effects of raloxifene and hormone replacement therapy on plasma nitric oxide concentrations, endothelin-1 levels and endothelium-dependent vasodilation in postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 21, 1512-1519 (2001).
59. Colacurci N, Manzella D, Fornaro F, Carbonella M, Paolisso G: Endothelial function and menopause: effects of raloxifene administration. J. Clin. Endocrinol. Metab. 88(5), 2135-2140 (2003).
60. Sbarouni E, Flevari P, Kroupis C et al.: The effects of rolaxifene and simvastatin on plasma lipids and endothelium. Cardiovasc. Drugs Ther. 17(4), 319-323 (2003).
61. Ceresini G, Marchini L, Rebecchi I et el.: Effects on raloxifene on carotid blood flow resistance and endothelium-dependent vasodilation in postmenopousal women. Atherosclerosis 167(1), 121-127 (2003).
62. da Costa LS, de Oliveira MA, Rubim VS et al.: Effects of hormone replacement therapy or raloxifene on ambulatory blood pressure and arterial stiffness in treated hypertensive postmenopousal women. Am. J. Cardiol. 94(11), 1453-1456 (2004).
63. Cagnacci A, Zanni AL, Volpe A: Administration of raloxifene deos not influence 24-hour ambulatory blood pressure of postmenopousal women with osteopenia: a doublle-blind placebo-controlled study. Am. J. Obstet. Gynecol. 188(5), 1278-1282 (2003).
64. Cagnacci A, Arangino S, Renzi A, Zanni AL, Volpe A: Raloxifene does not influence flow-mediated endothelium-dependent and endothelium-independent vasodilatation of osteopenic postmenopousal women. Am. J. Obster. Gynecol. 188(2), 313-317 (2003).
65. Cerquetani E, Vitale C, Mercuro G et al.: Comparative vascular effects of hormone replacement therapy and raloxifene in women at increased cardiovascular risk. Gynecol. Endocrinol. 18(6), 291-298 (2004).
66. Griffiths KA, Sader MA, Skilton MR, Harmer JA, Calermajer DS: Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. J. Am. Coll. Cardiol. 42(4), 698-704 (2003).
67. Barrett-Connor E, Grady D, Sashegyi A et al.: Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287(7), 847-857 (2002).
68. Mosca L, Barret-Connor E, Wenger NK et al.: Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am. J. Cardiol. 88(4), 392-395 (2001).
69. Keech CA, Sashegyi A, Barrett-Connor E: Year-by-year anlysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. Curr. Med. Res. Opin. 21(1), 135-140 (2005).
70. Blumenthal RS, Baranowski B, Dowsett SA: Cardiovascular effects of raloxifene: the arterial and venous systems. Am. Heart J. 147(5), 783-789 (2004).
71. Grady D, Herrington D, Bittner V et al.: Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288(1), 49-57 (2002).
72. Reis SE, Costantino JP, Wickerham DL et al.: Cardiovascular effects of tamoxifen in women with and without heart disease: Breast Cancer Prevention Trial. J. Natl Cancer Inst. 93(1), 16-21 (2001).
73. Cauley J, Norton L, Lippman ME et al.: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res. Treat. 65, 125-134 (2001).
74. Cuzick J, Powles T, Veronesi U et al.: Overview of the main outcomes in breast-cancer prevention trials. Lancet 361(9354), 296-300 (2003).
75. Cummings SR, Duong T, Kenyon E et al.: Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287(2), 216-220 (2002).
76. Vogel VG, Constantino JP, Wickerham DL, Cronin WM, Wolmark N: The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin. Breast Cancer 3(2), 153-159 (2002).
77. Freedman M, Martin JS, O'Gorman J et al.: Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J. Natl Cancer Inst. 93(1), 51-56 (2001).
78. Jackson VP, San Martin JA, Secrest RJ et al.: Comparison of the effect of raloxifene and continuoso-combined hormone therapy on mammographic breast denstiy and breast tenderness in postmenopausal women. Am. J. Obstet. Gynecol. 188(2), 389-394 (2003).
79. Christodoukas GE, Lambrinoudaki IV, Voursti AD et al.: Mammographic changes associated with raloxifene and tibolone theraphy in postmenopausal women: a prospective study. Menopause 9(2), 110-116 (2002).
80. Boss SM, Huster WJ, Neild JA et al.: Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am. J. Obstet. Gynecol. 177(6), 1458-1464 (1997).
81. Goldstein SR, Scheele WH, Rajagopalan SK et al.: A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet. Gynecol. 95(1), 95-103 (2000).
82. Davies GC, Huster WJ, Shen W et al.: Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. Menopause 6(3), 188-195 (1999).
83. Goldstein SR: The effect of SERMs on the endometrium. Ann. NY Acad. Sci. 949, 237-242 (2001).
84. Neven P, Lunde T, Benedetti-Panici P et al.: A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate. Br. J. Obstet. Gynaecol. 110(2), 157-167 (2003).
85. Grady D, Ettinger B, Moscarelli E et al.: Safety and adverse effects associated with raloxifene: Multiple Outcomes of Raloxifene Evaluation. Obstet. Gynecol. 104(4), 837-844 (2004).
86. Neven P, Quail D, Levrier M et al.: Uterine effects of estrogen plus progestin therapy and raloxifene: adjudicated results from the EURALOX study. Obstet. Gynecol. 103(5 Pt 1), 881-891 (2004).
87. de Azevedo GD, do Prado MF, Ferriani RA et al.: Raloxifene therapy does not affect uterine bloodflow in postmenopausal women: a transvaginal Doppler study. Maturitas 47(3), 195-200 (2004).
88. Martino S, Disch D, Dowsett SA, Keech CA, Mershon J: Safety assessment of raloxifene over eight years in a clinical trial settin. Curr. Med. Res. Opin. 21(9), 1441-1452 (2005).
89. Demichele A, Troxel A, Weber A et al.: Effect of raloxifene on endometrial cancer risk in a population-based, case control study. J. Clin. Oncol. 23 (Suppl.), 16S (2005).
90. Neven P, Goldstein SR, Ciaccia AV et al.: The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women. Gynecol. Oncol. 85(2), 388-390 (2002).
91. Grady D, Brown JS, Vittinghoff E et al.: Postmenopausal hormones and incontinence: the Heart and Estrogen/progestin Replacement Study. Obstet. Gynecol. 97(1), 116-120 (2001).
92. Goldstein SR, Nanavati N: Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am. J. Obstet. Gynecol. 187(3), 521-527 (2002).
93. Vardy MD, Lindsay R, Scotti RJ et al.: Short-term urogenital effects of raloxifene, tamoxifen, and estrogen. Am. J. Obstet. Gynecol. 189(1), 81-88 (2003).
94. Goldstein SR, Neven P, Zhou L et al.: Raloxifene effect on frequency of surgery for pelvic floor relaxation. Obstet. Gynecol. 98(1), 91-96 (2001).
95. Waetjen LE, Brown JS, Modelska K et al: Effect of raloxifene on urinary incontinence: a randomized controlled trial. Obstet. Gynecol. 103(2), 261-266 (2004).
96. Goldstein SR, Johnson S, Watts NB et al: Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen. Menopause 12(2), 160-164 (2005).
97. Craig MC, Maki PM, Murphy DG: The Women's Health Initiative Memory Study: findings and implications for treatment. Lancet Neurol. 4(3), 190-194 (2005).
98. Yaffe K, Krueger K, Sarkar S et al.: Cognitive function in postmenopausal women treated with raloxifene. N. Engl. J. Med. 344(16), 1207-1213 (2001).
99. Yaffe K: Estrogens, selective estrogen receptor modulators, and dementia: what is the evidence? Ann. NY Acad. Sci. 949, 215-222 (2001).
100. Littleton-Kearney MT, Ostrowski NL, Cox DA, Rossberg MI, Hum PD: Selective estrogen receptor modulators: tissue actions and potential for CNS protection. CNS Drug Rev. 8(3), 309-330 (2002).
101. Carranza-Lira S, MacGregor-Gooch AL, Sarachaga-Osterwalder M: Mood modifications with raloxifene and continuous combined estrogen plus progestin hormone therapy. Int. J. Fertil. Womens Med. 49(3), 120-122 (2004).
102. Haskell SG, Richardson ED: The effect of raloxifene on cognitive function in postmenopausal women: a randomized clinical trial. Conn. Med. 68(6), 355-358 (2004).
103. Yaffe K, Krueger K, Cummings SR et al.: Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am. J. Psychiatry 162(4), 683-690 (2005).
104. Cummings JL: Searching for methods to detect, prevent, and treat Alzheimer's disease. Am. J. Psychiatry 162(4), 645-647 (2005).
105. Davies GC, Huster WJ, Lu Y, Plouffe L, Lakshmanan M: Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet. Gynecol. 93(4). 558-565 (1999).
106. Cohen FJ, Lu Y: Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas 34(1), 65-73 (2000).
107. Aldright JM, Quail DC, Levy-Frebault J et al.: Predictors of hot flushes in postmenopausal women who receive raloxifene therapy. Am. J. Obstet. Gynecol. 191(6), 1979-1988 (2004).
108. Palacios S, Farias ML, Luebbert H et al.: Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate. Am. J. Obstet. Gynecol. 191(1), 121-131 (2004).
109. Martino S, Disch D, Dowsett SA, Keech CA, Mershon J: Safety assessment of raloxifene over eight years in a clinical trial setting. Curr. Med. Res. Opin. 21(9), 1441-1452 (2005).
110. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002).
111. Fisher B. Costantino, JP Wickerham DL et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90(18), 1371-1388 (1998).
112. Reindollar R, Koltun W, Parsons A et al.: Effects of oral raloxifene on serum estradiol levels and other markers of estrogenicity. Fertil. Steril. 78(3), 469-472 (2002).
113. Cheng WC, Yen ML, Hsu SH, Chen KH, Tsai KS: Effects of raloxifene, one of the selective estrogen receptor modulators, on pituitary-ovary axis and prolactin in postmenopausal women. Endocrine 23(2-3), 215-218 (2004).
114. Lasco A, Cannavo S, Gaudio A et al: Effects of long-lasting raloxifene treatment on serum prolactin and gonadotropin levels in postmenopausal women. Eur. J. Endocrinol. 147(4), 461-465 (2002).
115. Ceresini G, Morganti S, Rebecchi I et al.: A one-year follow-up on the effects of raloxifene on thyroid function in postmenopausal women. Menopause 11(2), 176-179 (2004).
116. Hsu SH, Cheng WC, Jang MW, Tsai KS: Effects of long-term use of raloxifene, a selective estrogen receptor modulator, on thyroid function test profiles. Clin. Chem. 47(10), 1865-1867 (2001).
117. Rubin MR, Lee KH, McMahon DJ, Silverberg SJ: Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 88(3), 1174-1178 (2003).
118. Kayser J, Ettinger B, Pressman A: Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen. Menopause 8(5), 328-332 (2001).
119. Turbi C, Herrero-Beaumont G, Acebes JC et al.: Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin. Ther. 26(2), 245-256 (2004).
120. Utian WH, Janata JW, Barbier S et al.: Effect of raloxifene on quality of life: a prospective study using the Utian Quality of Life (UQOL) scale. Menopause 11(3), 275-280 (2004).
121. Tosteson AN, Grove MR, Hammond CS et al.: Early discontinuation of treatment for osteoporosis. Am. J. Med. 115 (3), 209-216 (2003).
122. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J: Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48(3), 271-287 (2004).
123. Clowes JA, Peel NF, Eastell R: The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J. Clin. Endocrinol. Metab. 89(3), 1117-1123 (2004).
124. Unson CG, Siccion E, Gaztambide J et al.: Nonadherence and osteoporosis treatment preferences of older women: a qualitative study. J. Womens Health (Larchmt) 12(10), 1037-1045 (2003).
125. Segal E, Tamir A, Ish-Shalom S: Compliance of osteoporotic patients with different treatment regimens. Isr. Med. Assoc. J. 5(12), 859-862 (2003).